title: [Gemcitabine versus combined chemotherapy with 5-fluorouracil and cisplatin in advanced pancreatic cancer].
abstract: Gemcitabine hydrochloride (GEM) is a first-line therapeutic agent for advanced pancreatic cancer, but there is no established second-line treatment after GEM failure. We assessed the clinical benefit of systemic combined chemotherapy with 5-fluorouracil and cisplatin (FP therapy) in 19 patients compared with GEM in 32 patients, respectively. Tumor response rates were 10.5% and 15.6% for FP therapy and GEM, respectively. The median survival time in the FP therapy and GEM was 137 days and 241 days, respectively. Although clinical benefit was similar in both types of therapy, median survival time was more favorable for GEM, especially for Stage IVb. Nausea and vomiting were the most commonly observed toxicity in the FP therapy group. Our data indicate that FP therapy is not considered to be a useful second-line agent in patients with GEM pretreated pancreatic cancer.
authors.affiliation: Dept. of Gastroenterology, Saiseikai Second Hospital.
authors.forename: Hironobu
authors.initials: H
authors.lastname: Ohta
authors.forename: Takashi
authors.initials: T
authors.lastname: Ushiki
authors.forename: Ken-ichi
authors.initials: K
authors.lastname: Mizuno
authors.forename: Tadayuki
authors.initials: T
authors.lastname: Togashi
authors.forename: Kouji
authors.initials: K
authors.lastname: Watanabe
authors.forename: Keiichi
authors.initials: K
authors.lastname: Seki
authors.forename: Tooru
authors.initials: T
authors.lastname: Ishikawa
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Yoshida
authors.forename: Tomoteru
authors.initials: T
authors.lastname: Kamimura
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Baba
authors.forename: Yoshirou
authors.initials: Y
authors.lastname: Mafune
authors.forename: Naoki
authors.initials: N
authors.lastname: Ishikawa
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000401:mortality; D012189:Retrospective Studies; D015996:Survival Rate; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D002945:Cisplatin; D005472:Fluorouracil; D000093542:Gemcitabine